Biosimilars: Sandoz Pegfilgrastim Review, Amgen Adalimumab Launch Extended To 2018
Sandoz needs to do another study to satisfy FDA, while Amgen says it faces a slow pace of patent litigation with AbbVie.
You may also be interested in...
Following Sandoz’s Zarxio playbook, Pfizer plans to market Inflectra while patent litigation continues; February 2017 trial on cell culture media patent could answer question of potential damages.
Six-year-old biosimilar specialist could be first company to launch a biosimilar version of Neulasta, but the possibility of a biosimilar version of Humira has investors ogling.
'Amgen is speaking out of both sides of its mouth', AbbVie contends, promising suit on dozens more patents.